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ABSTRACT CTX-M-type extended-spectrum -lactamases (ESBLs) are widespread
among Enterobacterales strains worldwide. The most common variant is CTX-M-15,
which hydrolyzes ceftazidime at a high rate but spares carbapenems. Here, we iden-
tiﬁed CTX-M-33, a point mutation derivative of CTX-M-15 (Asp to Ser substitution at
Ambler position 109) that exhibited low carbapenemase activity. -Lactamase CTX-
M-33 was identiﬁed in a Klebsiella pneumoniae isolate, belonging to sequence type
405 and lacking the outer membrane protein OmpK36, that was resistant to broad-
spectrum cephalosporins and -lactam/-lactamase inhibitor combinations and dis-
played decreased susceptibility to carbapenems. Comparative hydrolytic activity as-
says showed that CTX-M-33 hydrolyzed ceftazidime at a lower level than CTX-M-15
but signiﬁcantly hydrolyzed meropenem. In addition, CTX-M-33 showed higher mu-
tant prevention concentration values and a wider mutant selection window in the
presence of meropenem, in accordance with its observed hydrolytic properties. Here,
we identiﬁed the very ﬁrst CTX-M enzyme possessing weak carbapenemase activity,
which may correspond to an emerging phenomenon, considering its possible evolu-
tion from the widespread ESBL CTX-M-15.
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The widespread diffusion and emergence of CTX-M-type extended-spectrum-lactamases (ESBLs) as a source of resistance to broad-spectrum cephalosporins in
Gram-negative organisms represent a phenomenon that was identiﬁed 20 years ago
(1). In contrast to the older ESBLs of the TEM and SHV types, which were identiﬁed
mostly in nosocomial Enterobacterales species such as Klebsiella pneumoniae, the CTX-M
enzymes emerged in community settings, mostly in Escherichia coli, and then were
found in many other enterobacterial species identiﬁed in hospital settings (2, 3).
CTX-M-1 was the ﬁrst identiﬁed CTX-M enzyme and exhibited a “cefotaximase” prop-
erty, hydrolyzing cefotaxime at high rates but almost sparing ceftazidime (4). Many
CTX-M derivatives have since been identiﬁed, such as CTX-M-15, which is a point
mutation derivative of CTX-M-3 that was ﬁrst identiﬁed in enterobacterial isolates from
India (5) and possesses the ability to hydrolyze ceftazidime very efﬁciently (6). CTX-M-15
rapidly became the most widespread ESBL determinant worldwide (4). One of the
consequences of the spread of CTX-M enzymes is the increased use of carbapenems for
treatment of infections caused by those ESBL producers, ultimately leading to the
selection of carbapenem-resistant bacteria, including carbapenemase producers.
The increasing prevalence of carbapenemase producers worldwide represents a
major threat, with enzymes such as KPC, NDM, and OXA-48 being almost endemic in
many geographical areas (7, 8). The acquisition of the latter resistance determinants is
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often superimposed on the spread of CTX-M-type ESBLs, as exempliﬁed by the very
high rate of isolates producing both types of enzymes. Nevertheless, acquired resis-
tance or decreased susceptibility to carbapenems has never been shown to be related
to the CTX-M enzymes gaining carbapenemase activity, in contrast to the rarely
identiﬁed GES-type ESBLs, among which variants such as -lactamases GES-2 and GES-5
exhibit signiﬁcant carbapenemase activity (9).
We recently performed a retrospective study aiming to evaluate the occurrence of
carbapenemase-producing Enterobacterales in a hospital in Lisbon, Portugal, during a
6-year period (10). An increase in the occurrence of carbapenemase-producing Enterobac-
terales over time was observed, with KPC-3 being the predominant carbapenemase but
OXA-181 also being found to be emerging. Among the carbapenem-nonsusceptible iso-
lates recovered in that study, a single K. pneumoniae isolate that was negative for the
known carbapenemases was recovered. Our aim here was to decipher the molecular and
biochemical bases of resistance in that isolate.
RESULTS
Susceptibility testing and molecular characterization. K. pneumoniae MAS9 was
recovered from rectal screening of a patient hospitalized in Lisbon, Portugal, in 2015. No
record of carbapenem-containing treatment was identiﬁed in the medical history of the
patient. This isolate was resistant to several -lactams, including broad-spectrum cephalo-
sporins, and displayed decreased susceptibility to carbapenems (Table 1). It was also
resistant to the -lactam/-lactamase inhibitor combinations amoxicillin-clavulanate and
piperacillin-tazobactam, remaining susceptible to ceftazidime-avibactam and ceftolozane-
tazobactam. In addition, this isolate was resistant to ﬂuoroquinolones, kanamycin, tobra-
mycin, co-trimoxazole, and tetracycline, remaining susceptible to amikacin, gentamicin,
tigecycline, and colistin. A positive result was obtained with the Rapid ESBL NP test (with
cefotaxime as the substrate [11]), whereas the Rapid Carba NP test (with imipenem as the
substrate [12]) result remained negative. PCR-based tests identiﬁed a blaCTX-M-like gene, and
sequencing of the corresponding amplicon identiﬁed the blaCTX-M-33 gene. The correspond-
ing enzyme, CTX-M-33, differed from CTX-M-15 by a single amino acid substitution, namely,
a Ser residue replacing an Asn residue at position Ambler 109. In addition, the isolate
possessed the blaTEM-1 -lactamase gene (data not shown).
Multilocus sequence typing (MLST) identiﬁed isolate MAS9 as belonging to se-
quence type 405 (ST405), and plasmid typing performed by PCR-based replicon typing
(PBRT) (13) showed that the blaCTX-M-33 gene was located on a plasmid belonging to
incompatibility group IncFIB. PCR mapping of the surrounding sequences of the
blaCTX-M-33 gene also showed that, as usually observed for the blaCTX-M-15 gene, the
blaCTX-M-33 gene was preceded by insertion sequence ISEcp1, which was likely respon-
sible for its acquisition on a plasmid and for its high-level expression (14, 15).
Cloning and expression of the ESBL gene. In order to compare the relative
resistance patterns mediated by CTX-M-33 and CTX-M-15, MICs for the recombinant
strains E. coli with pTOPO-CTX-M-33 and E. coli with pTOPO-CTX-M-15 were determined.
Notably, the ceftazidime MIC was signiﬁcantly lower for the CTX-M-33 producer, while
paradoxically the ceftazidime-avibactam MIC was slightly higher for the latter (Table 1).
In addition, the meropenem and imipenem MICs were slightly higher for the CTX-M-33
producer. This phenomenon was exacerbated when CTX-M-33 was produced in the
porin-deﬁcient E. coli HB4 strain, with signiﬁcantly higher meropenem and imipenem
MICs for the CTX-M-33 producer, compared to those for the CTX-M-15 producer in the
same strain background (Table 1). In the wild-type K. pneumoniae CIP53153 strain,
production of CTX-M-33 increased the carbapenem MICs only slightly (2-fold) (Table 1).
Notably, a peculiar phenomenon was observed when the ertapenem MICs for E. coli
strain HB4 and its corresponding recombinants were measured. While MICs measured
by Etest on Mueller-Hinton agar plates remained quite low and clear (neither double
zones nor colonies growing in the inhibition zone), those measured by broth microdi-
lution were found to be much higher (Table 1). Importantly, the ertapenem MIC
observed by broth microdilution for the CTX-M-33 producer was 8-fold higher than
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that for the CTX-M-15 producer (32 g/ml versus 4 g/ml) (Table 1), highlighting the
original property of CTX-M-33.
Kinetic study. Measurements of kinetic parameters were performed using puriﬁed
CTX-M-33 and CTX-M-15 enzymes. A signiﬁcant rate of meropenem hydrolysis by
CTX-M-33 was detected, whereas no hydrolysis could be detected with CTX-M-15 (Table
2). No hydrolysis could be detected with either enzyme with imipenem and ertapenem
as the substrates, although increased imipenem and ertapenem MIC values were
observed for the recombinant strains. Conversely, a 30-fold decreased rate of ceftazi-
dime hydrolysis was measured with CTX-M-33, compared to CTX-M-15, an 8-fold
decreased rate of amoxicillin hydrolysis, and a 3-fold decreased rate of piperacillin
hydrolysis.
Sensitivity to inhibitors. The 50% inhibitory concentration (IC50) values for CTX-
M-33 versus CTX-M-15 showed signiﬁcant decreases in the inhibitory capacities of the
different -lactamase inhibitors, as follows: clavulanic acid, 5-fold; tazobactam, 10-fold;
non--lactam inhibitor avibactam, 5.5-fold (Table 3).
Reduced outer membrane permeability of isolate MAS9. Since the weak carbap-
enemase activity could not directly explain the elevated carbapenem MICs observed,
particularly for ertapenem, it was suggested that isolate MAS9 might exhibit reduced
outer membrane permeability. Outer membrane protein (OMP) proﬁles clearly showed
that isolate MAS9 did not produce OmpK36, while OmpK35 and OmpK26 were present
(see Fig. S1 in the supplemental material). Molecular investigations showed that isolate
MAS9 possessed wild-type OmpK26 and OmpK35 porins, but the investigations iden-
tiﬁed a stop codon within the OmpK36 sequence (position 318 of the protein),
conﬁrming that the porin was deﬁcient in that isolate (data not shown).
Impact on mutant prevention concentrations. In order to evaluate whether the
differences observed in term of MIC values, which were found to be signiﬁcant in E. coli
HB4 but moderate in E. coli TOP10 and K. pneumoniae CIP53153, might play a role not
only in susceptibility to carbapenems but also in selection of resistant mutants, mutant
prevention concentration (MPC) determinations were performed using recombinant E.
coli TOP10 strains. The study showed that the production of CTX-M-33 raised the MPC
TABLE 2 Kinetic parameters of puriﬁed -lactamases CTX-M-33 and CTX-M-15
-Lactam
CTX-M-33a CTX-M-15
Kcat (s1) Km (M) Kcat/Km (M1 s1) Ki (M) Kcat (s1) Km (M) Kcat/Km (M1 s1) Ki (M)
Penicillin G 210 20 10 28 100 0.3
Amoxicillin 215 160 1.35 15 90 0.15
Ticarcillin 7.5 40 0.2 3.5 30 0.1
Piperacillin 205 140 1.5 16 35 0.5
Cephalothin 380 30 12.5 50 45 1
Cefepime 70 100 0.7 20 480 0.03
Cefotaxime 620 215 3 60 30 2.2
Ceftazidime 0.35 1,500 0.0003 15 1,500 0.01
Imipenem 0.01 ND ND 0.2 0.01 ND ND 0.6
Meropenem 0.13 90 0.0014 0.0024 0.01 ND ND 0.017
Ertapenem 0.01 ND ND 0.009 0.01 ND ND 0.007
Aztreonam 10 60 0.2 7 85 0.08
aStandard deviations were below 15%. ND, not determined due to a low initial rate of hydrolysis; kcat, catalytic efﬁciency; Km, Michaelis constant; kcat/Km, speciﬁcity
constant; Ki, relative; koff/kon, ratio.
TABLE 3 IC50 values for different -lactamase inhibitors against CTX-M-33 and CTX-M-15
-Lactamase
IC50 (nM)a
Clavulanic acid Tazobactam Avibactam
CTX-M-33 42  0.7 20  1.5 7.5  1.3
CTX-M-15 8.5  0.4 2  0.2 1.5  0.1
aIC50 represents the concentration of a drug that is required for 50% inhibition of the enzymatic activity. The
indicated values correspond to the means of three independent measurements, and the standard
deviations are indicated.
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values of imipenem and meropenem by 3- and 4-fold, respectively, compared to
CTX-M-15 (Table 4). The mutant selection window, corresponding to the MPC/MIC ratio,
was found to be 2 for meropenem (Table 4), while it remained the same for imipenem.
DISCUSSION
We showed here that decreased susceptibility to carbapenems may result from a
combination of porin deﬁciency and production of a CTX-M enzyme, as suggested
previously (16–18). We identiﬁed here a point mutation derivative of CTX-M-15 with
some carbapenemase activity. We acknowledge that this carbapenemase activity re-
mained relatively low; however, its impact was clearly seen with cloning in different
strain backgrounds, particularly in a porin-deﬁcient E. coli strain. In fact, by analyzing
the OMP proﬁle of isolate MAS9, we conﬁrmed that this clinical isolate presented
weaker permeability, since it lacked one OMP known to contribute signiﬁcantly to the
resistance to -lactams when absent, as shown in different studies (19, 20).
This CTX-M-33 enzyme was identiﬁed previously in a single carbapenem-susceptible
E. coli clinical isolate from Greece from 2002 (imipenem MIC of 1 g/ml but meropenem
MIC not determined) (21) and a single Aeromonas dhakensis isolate recovered from eel
in South Korea in 2014 (no data on carbapenem susceptibility) (22). This report is
another example among the rare ones of ESBLs that may evolve by point mutations
toward carbapenemase activity, after the report of GES and SHV derivatives (23, 24). The
carbapenemase activity reported here and occurring in a CTX-M-producing K. pneu-
moniae strain might be considered a serious cause for concern, due to global dissem-
ination of the CTX-M producers.
It was demonstrated previously that pleiotropic effects may be encountered upon
evolution of CTX-M -lactamases (25–27). For instance, reduced sensitivity of CTX-M-1,
CTX-M-2, or CTX-M-9-like enzymes to clavulanic acid or tazobactam (leading to in-
creased resistance to amoxicillin-clavulanic acid or piperacillin-tazobactam combina-
tions) was often accompanied by reduced hydrolytic activity toward broad-spectrum
cephalosporins, leading to greater susceptibility to those antibiotics (27). Here, we
showed that CTX-M-33, while gaining signiﬁcant hydrolytic activity toward mero-
penem, conversely showed signiﬁcant reduction of its sensitivity to inhibitors, including
avibactam, compared to CTX-M-15. This ﬁnding highlights that the Asn109Ser substi-
tution observed in CTX-M-33 led to decreased susceptibility to both carbapenems and
-lactam/-lactamase inhibitor combinations. Conversely, this pleiotropic effect was
observed in ceftazidime being less hydrolyzed by CTX-M-33 than by CTX-M-15.
Owing to the quite strong selective pressure with meropenem, which is used in
Portuguese hospitals to treat infections caused by ESBL-producing Enterobacterales
strains, and the spread of CTX-M-15 producers in this country (28), it is tempting to
speculate that this carbapenem molecule might have been a driving force to select for
the CTX-M-33 enzyme. Indeed, it is interesting to note that CTX-M-33 hydrolyzes
meropenem, while it does not signiﬁcantly hydrolyze imipenem and ertapenem.
By determining the Ki values of CTX-M-33 and CTX-M-15 for carbapenems, we
showed that the afﬁnity of CTX-M-33 for imipenem was higher, although no hydrolysis
was detectable. Such effects of CTX-M enzymes lacking obvious carbapenemase activity
against ertapenem or imipenem were already observed (16, 17), demonstrating that
those enzymes actually possess excellent afﬁnity for those substrates, to which they
strongly bind.
K. pneumoniae MAS9, producing CTX-M-33, belonged to ST405, which is a back-
ground previously identiﬁed in different parts of the world. It was particularly identiﬁed
TABLE 4MPC values of two carbapenems for E. coli DH10B recombinant strains
-Lactamase
Imipenem Meropenem
MIC (g/ml) MPC (g/ml) MPC/MIC MIC (g/ml) MPC (g/ml) MPC/MIC
CTX-M-33 0.75 18 24 0.125 0.667 5.3
CTX-M-15 0.25 6 24 0.064 0.167 2.6
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in K. pneumoniae isolates from Spain that coproduced CTX-M-15 and OXA-244 or
OXA-245 carbapenemases (29, 30). Considering the wide dissemination of this CTX-M-
15-producing ST405 clone in Spain, this ﬁnding supports the hypothesis that this clone
might also be widespread in the neighboring country Portugal, with which there are
many patient exchanges.
Further work will evaluate the possible dissemination of the blaCTX-M-33 gene,
particularly in the Iberic peninsula. Such ﬁndings underscore the value of sequencing
the entire resistance gene complement (rather than performing only PCR-based anal-
ysis) when performing epidemiological surveys, taking into account the fact that
CTX-M-33 and CTX-M-15 differ by only a single amino acid substitution. It remains to be
determined whether the selection of CTX-M-33 is just a preliminary step toward the
selection of CTX-M enzymes with higher carbapenemase activity. Taking into account
the large and community-located reservoir of CTX-M producers worldwide, such selec-
tion would signiﬁcantly compromise the efﬁcacy of all -lactam-containing antibiotic
regimens.
Finally, CTX-M-33 conferred decreased susceptibility to carbapenems and -lactamase
inhibitors. This phenomenon that we observed here with CTX-M-33 is the opposite of
ﬁndings observed with several KPC-type enzymes, with some variants reported to
confer resistance to ceftazidime-avibactam showing decreased ability to hydrolyze
carbapenems (31–34).
The biochemical properties of CTX-M-33 suggest that its selection may be the result
of (i) the use of carbapenems, leading to an ESBL possessing some carbapenemase
activity, or (ii) the use of ceftazidime-avibactam, leading to the selection of an ESBL
conferring resistance to those inhibitors. From a clinical point of view, these are
important considerations, since treatments of infections due to ESBL producers rely
mainly on either carbapenems or -lactam/-lactamase inhibitor combinations.
MATERIALS AND METHODS
Bacterial strains and plasmids. K. pneumoniae MAS9, producing CTX-M-33, and E. coli R1818,
producing CTX-M-15, were clinical isolates. Wild-type E. coli TOP10, E. coli HB4 (permeability defects due
to the loss of porins OmpC and OmpF), and wild-type K. pneumoniae CIP53153 were used as recipient
strains (35). Plasmid pTOPO (Invitrogen, Illkirch, France) was used as the shuttle vector for cloning and
expression in E. coli and K. pneumoniae recipient strains.
Susceptibility testing and -lactamase content. Susceptibility testing was performed ﬁrst by the
disk diffusion assay (Sanoﬁ-Diagnostic Pasteur, Marnes-la-Coquette, France). Results were interpreted
according to the CLSI guidelines (36). The MICs were then determined by Etest (AB bioMérieux; Solna,
Sweden) on Mueller-Hinton agar plates at 37°C. The antimicrobial agents were obtained from standard
laboratory powders and were used immediately after their solubilization. The agents and their sources
were as follows: amoxicillin, piperacillin, cefepime, cephalothin, ceftazidime, and clavulanic acid, Sigma
(Saint-Quentin Falavier, France); ticarcillin and cefoxitin, ROTH (Arlesheim, Switzerland); benzylpenicillin,
Abcam (Cambridge, UK); cefotaxime, kanamycin, and aztreonam, Acros Organic (Geel, Belgium); imi-
penem and meropenem, Carbosynth (Berkshire, UK); avibactam, MedChem Express (Lucerne, Switzer-
land). MICs were determined by an agar dilution technique on Mueller-Hinton agar (Bio-Rad, Marnes-la-
Coquette, France), with an inoculum of 104 CFU. All plates were incubated at 37°C for 18 h. MICs of
-lactams were determined alone or in combination with a ﬁxed concentration of clavulanic acid
(2 g/ml), tazobactam (4 g/ml), or avibactam (4 g/ml), following the most recent EUCAST recommen-
dations (www.eucast.org). Susceptibility to colistin was evaluated by broth microdilution (http://www
.eucast.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf). In
order to rapidly evaluate whether the K. pneumoniae clinical isolate produced an ESBL and/or a
carbapenemase, the Rapid ESBL NP and Rapid Carba NP tests were performed (11, 12).
Analysis of OMPs. OMP proﬁles were determined by SDS-PAGE analysis, as performed previously
(19). K. pneumoniae strain CIP53153 (wild-type phenotype) was used as a negative control, and K.
pneumoniae strain 11978 (lacking the OmpK36 OMP) was used as a positive control (19).
In parallel, molecular investigations were performed in order to characterize the genetic bases of the
OMP proﬁles. PCR ampliﬁcations of genes encoding OmpK36, OmpK35, and OmpK26 were performed
using primers OmpK36-Fw (5=-GCAGTGGCATAATAAAAGGCA-3=) and OmpK36-Rv (5=-ACTGGTAAACCAG
GCCCAG-3=), OmpK35-Fw (5=-AACTTATTGACGGCAGTGGC-3=) and OmpK35-Rv (5=-TTGGTAAACGATACCC
ACGG-3=), and OmpK26-Fw (5=-ATGTTAAAACGCTCTCTGGT-3=) and OmpK26-Rv (5=-TCAGAACGAGTAGG
CCAC-3=), respectively, followed by sequencing of the corresponding amplicons.
Determination of MPCs. For MPC measurements, E. coli TOP10 recombinant strains producing
CTX-M-33 or CTX-M-15 were inoculated into 100 ml of Mueller-Hinton broth (MHB) and then incubated
overnight at 37°C. After incubation, cultures were estimated to have concentrations of3 108 CFU/ml.
Cultures were then centrifuged at 5,000 g for 30 min and resuspended in 6 ml of MHB. Meropenem-
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or imipenem-supplemented agar plates were inoculated with 200-l aliquots of the respective cultures,
corresponding to bacterial amounts of 1010 CFU. Inoculated plates were incubated for 48 h at 37°C.
MPC was recorded as the lowest antibiotic concentration for which no growth was observed, as
described (37).
Molecular characterization and cloning experiments. Whole-cell DNA was extracted from K.
pneumoniae MAS9 using the QIAamp minikit (Qiagen, Courtaboeuf, France), according to the manufac-
turer’s recommendations, and the corresponding DNA was used as the template for detection of several
-lactamase genes using speciﬁc primers (38). Sequencing of the amplicons was performed by the
Sanger technique (Microsynth, Balgach, Switzerland). MLST was performed as recommended (https://
cge.cbs.dtu.dk/services/MLST). In order to evaluate and to compare the spectrum of hydrolysis of
CTX-M-33 to that of CTX-M-15, cloning of the blaCTX-M-33 and blaCTX-M-15 genes was performed using the
high-copy pTOPO vector (Invitrogen), followed by expression in the same E. coli backgrounds (either E.
coli TOP10 or E. coli HB4) or K. pneumoniae CIP53153.
Selection was based on plates containing ampicillin (100 g/ml) and kanamycin (30 g/ml) or
cefotaxime (1 g/ml) and kanamycin (30 g/ml) for E. coli and K. pneumoniae, respectively. The PCR
amplicons encompassing the entire sequences of the blaCTX-M genes used for cloning were obtained by
using primers CTX-M-Fw (5=-GAGCTCGCTCTGTGGATAACTTGCAG-3=) and CTX-M-Rv (5=-GGATCCTTACAA
ACCGTCGGTGACGA-3=).
-Lactamase puriﬁcation. Cultures of E. coli TOP10 harboring plasmid pTOPO-CTX-M-33 or pTOPO-
CTX-M-15 were grown overnight at 37°C in 1 liter of brain heart infusion broth with amoxicillin
(100 g/ml). The bacterial suspension was pelleted, resuspended in 10 ml of 100 mM phosphate buffer
(pH 7), and disrupted by soniﬁcation. This suspension was dialyzed overnight against 20 mM 2-(N-
morpholino)ethanesulfonic acid (MES) (pH 6) at 4°C. The enzyme extract was loaded onto a preequili-
brated HiTrap SP XL column (GE Healthcare) with the same buffer. Proteins were then eluted with a linear
NaCl gradient (from 0 to 0.5 M). The fractions showing the highest -lactamase activity were pooled and
dialyzed against 100 mM phosphate buffer (pH 7.0), prior to 10-fold concentration with a Vivaspin 20
concentrator (GE Healthcare). The puriﬁed -lactamase extract was immediately used for enzymatic
determinations.
Determination of -lactamase relative molecular mass. The relative purity of -lactamase CTX-
M-33 was estimated by SDS-12% PAGE analysis. Enzyme extracts and marker proteins were boiled for
10 min in a 1% SDS-3% -mercaptoethanol solution and then were subjected to electrophoresis at room
temperature.
Kinetic measurements. Puriﬁed -lactamase was used for kinetic measurements performed at 30°C
in 100 mM sodium phosphate (pH 7.0). The initial rates of hydrolysis were determined with a Genesys 10S
UV-visible spectrophotometer (Thermo Scientiﬁc). The following wavelengths and absorption coefﬁ-
cients were used: benzylpenicillin, 232 nm and  of 1,100 M1 cm1; amoxicillin, 240 nm and  of
1,100 M1 cm1; ticarcillin, 235 nm and  of 1,050 M1 cm1; piperacillin, 235 nm and  of 1,070
M1 cm1; cephalothin, 262 nm and  of 7,960 M1 cm1; cefoxitin, 265 nm and  of 7,380
M1 cm1; ceftazidime, 260 nm and  of 8,660 M1 cm1; cefepime, 264 nm and  of 8,240
M1 cm1; cefotaxime, 265 nm and  of 6,260 M1 cm1; imipenem, 297 nm and  of 9,210
M1 cm1; meropenem, 297 nm and  of 9,210 M1 cm1; aztreonam, 318 nm and  of 640
M1 cm1.
The Ki values were determined by direct competition assays using 100 M nitroceﬁn. Inverse initial
steady-state velocities (1/V0) were plotted against the inhibitor concentration ([I]) to obtain a straight line.
The plots were linear and provided y intercept and slope values used for Ki determinations. Ki was
determined by dividing the value for the y intercept by the slope of the line and then was corrected by
taking into account the nitroceﬁn afﬁnity, using the following equation: Ki (corrected) 	 Ki (observed)/(1
 [S]/Km), where [S] is the concentration of nitroceﬁn (100 M) used in the assay and Km is the Michaelis
constant determined for nitroceﬁn (8.5 M for CTX-M-33 and 15.4 M for CTX-M-15).
Sensitivity to -lactamase inhibitors. IC50 values were determined for clavulanic acid, tazobactam,
and avibactam. Various concentrations of these inhibitors were preincubated with the puriﬁed enzymes
CTX-M-15 and CTX-M-33 for 5 min at 30°C, to determine the concentrations that reduced the hydrolysis
rate with 100 M cephalothin by 50%. The results are expressed in nanomolar units. The total protein
content was measured by using a Bradford assay.
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